Celldex Therapeutics (CLDX) EBT Margin (2010 - 2026)
Celldex Therapeutics' (CLDX) quarterly EBT Margin came in at 572686.67% in Q1 2026, down 56367228.0% year-on-year from N/an in Q1 2025, and down 532.14% quarter-over-quarter from 90594.21% in Q4 2025.
Celldex Therapeutics (CLDX) EBT Margin (2010 - 2026) Analysis & Trends
Celldex Therapeutics' EBT Margin history runs 17 years deep, the most recent figure standing at 572686.67% for Q1 2026.
- On a quarterly basis, EBT Margin fell 56367228.0% year-over-year to 572686.67% in Q1 2026; TTM through Mar 2026 was 37733.6%, a 3112479.0% decrease from a year earlier, with the FY2025 full-year figure at 42819.42%, down 3601573.0% from the prior year.
- EBT Margin declined to 572686.67% in Q1 2026 per CLDX's latest filing, from 90594.21% in the prior quarter.
- Across five years, EBT Margin topped out at 1523.91% in Q3 2024 and bottomed at 572686.67% in Q1 2026.
- The 5-year median for EBT Margin is 9235.98% (2023), against an average of 50767.35%.
- Across the five-year window, EBT Margin surged 1806510 bps in 2025 and slumped 56367228 bps in 2026, its largest moves.
- Year by year, EBT Margin stood at 1642.1% in 2022, then slumped by 476 bps to 9457.56% in 2023, then slumped by 206 bps to 28982.81% in 2024, then sank by 213 bps to 90594.21% in 2025, then sank by 532 bps to 572686.67% in 2026.
- Per Business Quant, the three latest CLDX EBT Margin figures stand at 572686.67% (Q1 2026), 90594.21% (Q4 2025), and 8795.07% (Q2 2025).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 17.13% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 41.95% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 23.05% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 34.77% |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Celldex Therapeutics | 1.72 Mn | 1.72 Mn | -1.44 Mn | -572,686.67% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -572,686.67% |
| Dec 31, 2025 | -90,594.21% |
| Jun 30, 2025 | -8,795.07% |
| Mar 31, 2025 | -9,014.39% |
| Dec 31, 2024 | -28,982.81% |
| Sep 30, 2024 | -1,523.91% |
| Jun 30, 2024 | -1,910.89% |
| Mar 31, 2024 | -27,079.49% |
| Dec 31, 2023 | -9,457.56% |
| Sep 30, 2023 | -2,744.89% |
| Jun 30, 2023 | -12,605.60% |
| Mar 31, 2023 | -3,323.68% |
| Dec 31, 2022 | -1,642.10% |
| Sep 30, 2022 | -6,580.84% |
| Jun 30, 2022 | -22,088.34% |
| Mar 31, 2022 | -13,247.13% |
| Dec 31, 2021 | -6,032.34% |
| Sep 30, 2021 | -13,515.69% |
| Jun 30, 2021 | -384.28% |
| Mar 31, 2021 | -2,414.31% |